MedTrace Logo

RAD001 in Advanced Sarcoma

NCT01830153 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2013-04-12

No results posted yet for this study

Summary

This trial intends to test the efficacy and safety of RAD001 in patients with advanced sarcoma who failed to conventional chemotherapy.

Conditions

  • Soft Tissue Sarcomas
  • Bone Sarcomas

Interventions

DRUG

RAD001

Sponsors & Collaborators

  • Novartis

    collaborator INDUSTRY

  • Asan Medical Center

    lead OTHER

Principal Investigators

  • Jin-Hee Ahn, MD, PhD · Asan Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2013-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01830153 on ClinicalTrials.gov